Solving the puzzle of what makes immunotherapies work

The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to understand the mechanistic drivers of efficacy and the identification of novel biomarkers that enrich for patients who benefit from ICB therapy. Here, we provide a perspective on emerging biomarker candidates, their underlying biological mechanisms, and how they may fit into the current landscape of ICB biomarkers. We discuss new frameworks to identify and evaluate biomarker candidates and review the opportunities and challenges of utilizing biomarker-derived models to facilitate the development of new immunotherapies.

Automated summary

This article discusses the demand and opportunities brought about by the rapid adoption of immune checkpoint blockade therapy. It presents new biomarker candidates and investigates their biological mechanisms and how they fit into the existing landscape of ICB biomarkers. Additionally, the article discusses the challenges of using biomarker-derived models to facilitate the development of new immunotherapies.